STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

Valentina Cannone, Mark Ledwidge, Chris Watson, Paul M McKie, John C Burnett, Kenneth McDonald

Research output: Contribution to journalArticlepeer-review

6 Downloads (Pure)

Abstract

B-type natriuretic peptide (BNP) possesses blood-pressure-lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.

Original languageEnglish
Pages (from-to)497-504
Number of pages8
JournalJACC: Basic to Translational Science
Volume6
Issue number6
DOIs
Publication statusPublished - 16 Jun 2021

Bibliographical note

© 2021 The Authors.

Fingerprint

Dive into the research topics of 'STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure'. Together they form a unique fingerprint.

Cite this